Sarepta’s gene therapy program for Duchenne resumes after clinical trial hold lifted
The FDA lifted a clinical hold on Sarepta’s early-stage clinical trial for a gene therapy for Duchenne muscular dystrophy, putting the company's plans back on schedule.
Sarepta’s early-stage clinical trial for a gene therapy for Duchenne muscular dystrophy is back on schedule, the company announced Monday. The Food and Drug Administration in July.
